Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: 6/1/2007
Phase: III
A randomized double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Genetic Substudy Associated With the Avastin {Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: 4/18/2008
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-Small Cell Lung Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Product Name: Epothilone D
Date of Report: To be Published
Phase: II
A Study of Epothilone D in Patients with Non–Small Cell Lung Cancer
Product Name: pertuzumab
Date of Report: To be Published
Phase: I
A Study of Pertuzumab in Combination With Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: 3/31/2004
Phase: III
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Tarceva (Erlotinib) plus Chemotherapy (Cisplatin and Gemcitabine) Versus Chemotherapy Alone in Patients with Advanced (Stage IIIB or IV) Non–Small-Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Patients With Non–Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non–Small Cell Lung Cancer (NSCLC)
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
MERIT study A Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: III
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: IV
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated With Tarceva (Erlotinib).
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: I
A Study of Tarceva (Erlotinib) in Combination With Alimta in Patients With Non-Small Cell Lung Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer.
